Stockhouse28d
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
impact on tissue health (histology) as measured by EoEHSS, and the measurement of peak eosinophil count ("PEC"). "In the RESOLVE trial, positive efficacy and safety outcomes continue to be observed," ...
Newswire28d
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
impact on tissue health (histology) as measured by EoEHSS, and the measurement of peak eosinophil count ("PEC"). "In the RESOLVE trial, positive efficacy and safety outcomes continue to be ...